Predicting progression-free survival in sarcoma using MRI-based automatic segmentation models and radiomics nomograms: a preliminary multicenter study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
OBJECTIVES: Some sarcomas are highly malignant, associated with high recurrence despite treatment. This multicenter study aimed to develop and validate a radiomics signature to estimate sarcoma progression-free survival (PFS). MATERIALS AND METHODS: The study retrospectively enrolled 202 consecutive patients with pathologically diagnosed sarcoma, who had pre-treatment axial fat-suppressed T2-weighted images (FS-T2WI), and included them in the ROI-Net model for training. Among them, 120 patients were included in the radiomics analysis, all of whom had pre-treatment axial T1-weighted and transverse FS-T2WI images, and were randomly divided into a development group (n = 96) and a validation group (n = 24). In the development cohort, Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression was used to develop the radiomics features for PFS prediction. By combining significant clinical features with radiomics features, a nomogram was constructed using Cox regression. RESULTS: The proposed ROI-Net framework achieved a Dice coefficient of 0.820 (0.791-0.848). The radiomics signature based on 21 features could distinguish high-risk patients with poor PFS. Univariate Cox analysis revealed that peritumoral edema, metastases, and the radiomics score were associated with poor PFS and were included in the construction of the nomogram. The Radiomics-T1WI-Clinical model exhibited the best performance, with AUC values of 0.947, 0.907, and 0.924 at 300 days, 600 days, and 900 days, respectively. CONCLUSION: The proposed ROI-Net framework demonstrated high consistency between its segmentation results and expert annotations. The radiomics features and the combined nomogram have the potential to aid in predicting PFS for patients with sarcoma.